Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization
Tong Ye,Zhouguang Jiao,Xin Li,Zhanlong He,Yanyan Li,Fengmei Yang,Xin Zhao,Youchun Wang,Weijin Huang,Meng Qin,Yingmei Feng,Yefeng Qiu,Wenhui Yang,Lingfei Hu,Yaling Hu,Yu Zhai,Erqiang Wang,Di Yu,Shuang Wang,Hua Yue,Yishu Wang,Hengliang Wang,Li Zhu,Guanghui Ma,Wei Wei
DOI: https://doi.org/10.1038/s41586-023-06809-8
IF: 64.8
2023-12-14
Nature
Abstract:The COVID-19 pandemic has fostered major advances in vaccination technologies 1,2,3,4 ; however, there are urgent needs for vaccines that induce mucosal immune responses and for single-dose, non-invasive administration 4,5,6 . Here we develop an inhalable, single-dose, dry powder aerosol SARS-CoV-2 vaccine that induces potent systemic and mucosal immune responses. The vaccine encapsulates assembled nanoparticles comprising proteinaceous cholera toxin B subunits displaying the SARS-CoV-2 RBD antigen within microcapsules of optimal aerodynamic size, and this unique nano–micro coupled structure supports efficient alveoli delivery, sustained antigen release and antigen-presenting cell uptake, which are favourable features for the induction of immune responses. Moreover, this vaccine induces strong production of IgG and IgA, as well as a local T cell response, collectively conferring effective protection against SARS-CoV-2 in mice, hamsters and nonhuman primates. Finally, we also demonstrate a mosaic iteration of the vaccine that co-displays ancestral and Omicron antigens, extending the breadth of antibody response against co-circulating strains and transmission of the Omicron variant. These findings support the use of this inhaled vaccine as a promising multivalent platform for fighting COVID-19 and other respiratory infectious diseases.
multidisciplinary sciences